Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2024-05-16 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
申万宏源证券承销保荐有限责任公司关于北京星昊医药股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from the underwriting and sponsoring institution regarding the company's use of temporarily idle raised funds for cash management. It includes specifics about the fundraising, usage progress, storage, investment purpose, risk analysis, and approvals by the board and supervisory committee. The document is not a brief announcement but a substantive report on the use of raised capital funds, including financial figures and regulatory compliance. It is not an announcement of a report publication, nor a certification letter. The content aligns with a Capital/Financing Update (CAP) as it discusses fundraising proceeds and their management, usage, and investment plans in detail.
2024-05-16 Chinese
第六届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results on specific proposals related to the use of idle raised funds and opening of special accounts for raised funds. There is no financial data or comprehensive report content, but rather a disclosure of board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document is short (1287 characters) and does not contain financial statements or detailed analysis, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing or Report Publication Announcement because it contains substantive meeting resolution content rather than just a notice or certification. Therefore, the best classification is MANG with high confidence.
2024-05-15 Chinese
使用闲置募集资金购买理财产品公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the use of idle raised funds to purchase financial products. It details the amount of funds raised, their usage status, reasons for temporary idleness, the types of financial products to be purchased, investment decision-making, risk control measures, and opinions from the supervisory board and sponsoring institution. The document is about the company's fundraising capital usage and management, specifically the use of idle raised funds for financial management purposes. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The document is a capital/financing update related to the use of raised funds and their temporary investment in financial products. The document length is under 5,000 characters but contains substantive information about capital usage, not merely an announcement of a report publication. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-05-15 Chinese
第七届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of a proposal regarding the use of idle raised funds to purchase financial products. It references another announcement (公告编号：2024-040) for detailed content. The document is short (788 characters) and primarily serves as an official meeting resolution announcement rather than a full report or financial statement. It does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-05-15 Chinese
2023年股权激励计划部分股票期权注销完成公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the cancellation of part of a stock option plan by Beijing Xinghao Pharmaceutical Co., Ltd. It details the number of stock options cancelled, the relevant regulatory guidelines, and the impact on the company's financial status. The document is short (1016 characters) and focuses on a specific corporate action related to stock options, which is a capital structure change. It is not a full financial report, audit, or management discussion. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements about new share issues, stock splits, or other capital changes such as stock option cancellations.
2024-05-14 Chinese
持股5%以上股东减持股份计划公告（再次披露）
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder holding more than 5% of the company's shares planning to reduce their holdings. It details the shareholder's identity, the number and percentage of shares held, the planned reduction amount, methods, timing, and compliance with relevant regulations. It also references previous disclosures and confirms no breach of prior commitments. The content focuses on shareholding changes by a major shareholder and their planned share reduction, which aligns with the definition of a Major Shareholding Notification (MRQ). The document is not a full financial report, earnings release, or management report, nor is it an announcement of a report publication. Therefore, the appropriate classification is MRQ.
2024-04-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.